Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and tolerance of the association of
two drugs already marketed and used to treat your disease: Arimidex® 1 Mg per day per os and
Zoladex® 3,6 Mg in injections under cutaneous once per month in subjects with breast cancer.